After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Pliant Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Pliant Therapeutics Inc is $89.63M. A total of 0.98 million shares were traded on the day, compared to an average of 2.74M shares.
In the most recent transaction, Coulie Bernard sold 52,419 shares of PLRX for 11.20 per share on Jan 17 ’25. After the transaction, the President and CEO now owns 430,517 company shares. In a previous transaction on Jan 17 ’25, Cummings Keith Lamont sold 20,148 shares at 11.20 per share. PLRX shares that Chief Financial Officer owns now total 262,608.
Among the insiders who sold shares, Hull Hans disposed of 15,936 shares on Jan 17 ’25 at a per-share price of $11.20. This resulted in the Chief Business Officer holding 211,558 shares of PLRX after the transaction. In another insider transaction, Lefebvre Eric sold 18,478 shares at $11.20 per share on Jan 17 ’25. Company shares held by the Chief Medical Officer now total 194,574.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, PLRX has a high of $16.52 and a low of $1.10.
As of this writing, PLRX has an earnings estimate of -$0.75 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.87.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PLRX’s latest balance sheet shows that the firm has $200.60M in Cash & Short Term Investments as of fiscal 2021. There were $7.19M in debt and $16.83M in liabilities at the time. Its Book Value Per Share was $5.00, while its Total Shareholder’s Equity was $199.06M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PLRX is Buy with a score of 3.31.
